Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JOSE ANTONIO KARAM and SURENA MATIN.
JOSE ANTONIO KARAM
Connection Strength
9.512
SURENA MATIN
  1. Author reply. Urology. 2016 Jan; 87:222-3.
    View in: PubMed
    Score: 0.534
  2. Positive Margins after Radical Nephrectomy with Venous Thrombectomy: Controversies and Treatment Options. J Urol. 2016 Feb; 195(2):241-2.
    View in: PubMed
    Score: 0.529
  3. Salvage surgery after energy ablation for renal masses. BJU Int. 2015 Jan; 115(1):74-80.
    View in: PubMed
    Score: 0.498
  4. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710.
    View in: PubMed
    Score: 0.452
  5. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005.
    View in: PubMed
    Score: 0.440
  6. Ablation of kidney tumors. Surg Oncol Clin N Am. 2011 Apr; 20(2):341-53, viii.
    View in: PubMed
    Score: 0.376
  7. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7.
    View in: PubMed
    Score: 0.370
  8. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274. Eur Urol Oncol. 2024 Apr; 7(2):302-303.
    View in: PubMed
    Score: 0.231
  9. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2024 Apr; 7(2):266-274.
    View in: PubMed
    Score: 0.225
  10. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 05 10; 14(1):2684.
    View in: PubMed
    Score: 0.222
  11. Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urological surgery. BJU Int. 2022 05; 129(5):585-587.
    View in: PubMed
    Score: 0.204
  12. Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Clin Genitourin Cancer. 2022 08; 20(4):e330-e338.
    View in: PubMed
    Score: 0.204
  13. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805. BJU Int. 2022 06; 129(6):718-722.
    View in: PubMed
    Score: 0.199
  14. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol. 2021 12; 39(12):837.e9-837.e17.
    View in: PubMed
    Score: 0.199
  15. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23.
    View in: PubMed
    Score: 0.196
  16. Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. Transl Androl Urol. 2021 May; 10(5):2233-2245.
    View in: PubMed
    Score: 0.193
  17. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer. 2018 10 15; 124(20):4023-4031.
    View in: PubMed
    Score: 0.162
  18. Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int. 2019 03; 123(3):447-455.
    View in: PubMed
    Score: 0.161
  19. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034.
    View in: PubMed
    Score: 0.158
  20. Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. J Urol. 2018 02; 199(2):393-400.
    View in: PubMed
    Score: 0.150
  21. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953.
    View in: PubMed
    Score: 0.149
  22. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 08; 198(2):281-288.
    View in: PubMed
    Score: 0.145
  23. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84.
    View in: PubMed
    Score: 0.136
  24. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
    View in: PubMed
    Score: 0.133
  25. Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol. 2015 Dec; 33(12):528-37.
    View in: PubMed
    Score: 0.132
  26. Comparison of Single-docking Robotic-assisted and Traditional Laparoscopy for Retroperitoneal Lymph Node Dissection During Nephroureterectomy With Bladder Cuff Excision for Upper-tract Urothelial Carcinoma. Urology. 2016 Jan; 87:216-23.
    View in: PubMed
    Score: 0.132
  27. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int. 2016 May; 117(5):775-82.
    View in: PubMed
    Score: 0.129
  28. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
    View in: PubMed
    Score: 0.128
  29. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2015 Jul; 116(1):85-92.
    View in: PubMed
    Score: 0.126
  30. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22.
    View in: PubMed
    Score: 0.126
  31. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
    View in: PubMed
    Score: 0.126
  32. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol. 2015 Jun; 67(2):149-56.
    View in: PubMed
    Score: 0.125
  33. Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol. 2015 Apr; 193(4):1101-7.
    View in: PubMed
    Score: 0.123
  34. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42.
    View in: PubMed
    Score: 0.117
  35. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7.
    View in: PubMed
    Score: 0.109
  36. Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma. J Endourol. 2011 Aug; 25(8):1323-7.
    View in: PubMed
    Score: 0.098
  37. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44.
    View in: PubMed
    Score: 0.094
  38. Magnetic-Resonance-Imaging-Guided Cryoablation for Solitary-Biopsy-Proven Renal Cell Carcinoma: A Tertiary Cancer Center Experience. Cancers (Basel). 2024 May 10; 16(10).
    View in: PubMed
    Score: 0.060
  39. YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
    View in: PubMed
    Score: 0.059
  40. Magnetic resonance imaging-guided renal biopsy shows high safety and diagnostic yield: a tertiary cancer center experience. Eur Radiol. 2024 Sep; 34(9):5551-5560.
    View in: PubMed
    Score: 0.059
  41. Effectiveness of Thermal Ablation for Renal Cell Carcinoma after Prior Partial Nephrectomy. Eur Urol Open Sci. 2023 Nov; 57:45-50.
    View in: PubMed
    Score: 0.057
  42. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology. 2023 12; 182:168-174.
    View in: PubMed
    Score: 0.057
  43. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610. Eur Urol Oncol. 2023 12; 6(6):638-639.
    View in: PubMed
    Score: 0.056
  44. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6. Eur Urol. 2023 08; 84(2):e55-e56.
    View in: PubMed
    Score: 0.056
  45. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci. 2023 Apr; 50:43-46.
    View in: PubMed
    Score: 0.055
  46. Outcomes of Radiofrequency Ablation for Solitary T1a Renal Cell Carcinoma: A 20-Year Tertiary Cancer Center Experience. Cancers (Basel). 2023 Jan 31; 15(3).
    View in: PubMed
    Score: 0.055
  47. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
    View in: PubMed
    Score: 0.050
  48. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620.
    View in: PubMed
    Score: 0.049
  49. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. AJR Am J Roentgenol. 2021 07; 217(1):157-163.
    View in: PubMed
    Score: 0.048
  50. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.
    View in: PubMed
    Score: 0.047
  51. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020 12; 126(6):745-753.
    View in: PubMed
    Score: 0.046
  52. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020 09 01; 126(17):3950-3960.
    View in: PubMed
    Score: 0.045
  53. Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. Adv Radiat Oncol. 2020 May-Jun; 5(3):495-502.
    View in: PubMed
    Score: 0.044
  54. Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. Eur Urol Focus. 2021 03; 7(2):397-403.
    View in: PubMed
    Score: 0.044
  55. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707.
    View in: PubMed
    Score: 0.042
  56. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol. 2018 11; 188(11):2487-2496.
    View in: PubMed
    Score: 0.040
  57. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2020 01 15; 6(1):104-111.
    View in: PubMed
    Score: 0.040
  58. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World J Urol. 2018 Dec; 36(12):1973-1980.
    View in: PubMed
    Score: 0.040
  59. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018 05 28; 39(6):752-757.
    View in: PubMed
    Score: 0.039
  60. Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology. 2018 Jun; 116:114-119.
    View in: PubMed
    Score: 0.039
  61. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World J Urol. 2018 Jul; 36(7):1093-1101.
    View in: PubMed
    Score: 0.039
  62. The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology. 2018 May; 115:119-124.
    View in: PubMed
    Score: 0.039
  63. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer. 2018 04; 16(2):e443-e450.
    View in: PubMed
    Score: 0.038
  64. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017 Sep 15; 123(18):3617-3627.
    View in: PubMed
    Score: 0.037
  65. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.036
  66. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.036
  67. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
    View in: PubMed
    Score: 0.036
  68. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. Br J Cancer. 2017 01 03; 116(1):77-84.
    View in: PubMed
    Score: 0.036
  69. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res. 2016 Apr 15; 22(8):2074-82.
    View in: PubMed
    Score: 0.033
  70. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.033
  71. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer. 2016 Jan 01; 122(1):108-15.
    View in: PubMed
    Score: 0.033
  72. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 05; 35(21):2687-97.
    View in: PubMed
    Score: 0.033
  73. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.032
  74. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.032
  75. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
    View in: PubMed
    Score: 0.032
  76. Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World J Urol. 2014 Feb; 32(1):265-71.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.